Financials · PROK

ProKidney Corp. (PROK) financials

For the twelve months ended Sep 30, 2026, ProKidney Corp. reported $775.0K of revenue and -$103.28M of net income.

Revenue, TTM
$775.0K
Revenue growth, YoY
+4.2%
Net income, TTM
-$103.28M
Net margin
-13326.7%
Free cash flow, TTM
-$167.83M
Cash
$81.36M
P/S
403.84
Market cap
$313.0M
Annual revenue$893.0K
FY2022FY2025
Annual net income-$68.99M
FY2020FY2025
Annual free cash flow-$135.31M
FY2020FY2025

PROK revenue and earnings growth

PROK revenueQ3 2026$174.0K

Quarter YoY
-19.8%
QoQ
+16.0%
FY YoY
12x

PROK revenue was $174.0K in fiscal Q3 2026 (ended Sep 30, 2026), down 19.8% from a year earlier and up 16.0% from the prior quarter. For the full fiscal 2025 it was $893.0K, up about 12-fold from fiscal 2024.

PROK net incomeQ3 2026-$35.59M

PROK net income was -$35.59M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$16.47M a year earlier. For the full fiscal 2025 it was -$68.99M, compared with -$61.19M in fiscal 2024.

PROK free cash flowQ3 2026-$39.88M

PROK free cash flow was -$39.88M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$31.79M a year earlier. For the full fiscal 2025 it was -$135.31M, compared with -$155.86M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Revenue$893.0K$76.0K$0$0--
Research and development$114.12M$127.67M$106.71M$82.07M$46.26M$21.04M
Selling, general and admin$51.78M$56.08M$44.81M$70.94M$8.86M$5.98M
Operating income-$165.01M-$183.68M-$151.52M-$153.01M-$55.11M-$27.02M
Interest expense$4.0K$9.0K$12.0K$215.0K$0$0
Pre-tax income-$151.20M-$163.93M-$129.45M-$147.24M-$55.11M-$26.98M
Income tax$414.0K-$598.0K$6.00M$896.0K$38.0K-$232.0K
Net income-$68.99M-$61.19M-$35.47M-$148.13M-$55.15M-$26.75M
EPS, basic----$0.23--
EPS, diluted----$0.23--
Diluted shares---61.5M--

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Cash and equivalents$108.54M$99.12M$60.65M$490.25M$20.56M$4.58M
Current assets$280.68M$395.88M$374.15M$504.72M$27.27M-
Total assets$335.57M$441.07M$420.55M$518.00M$40.30M-
Current liabilities$30.74M$36.22M$25.04M$10.87M$12.31M-
Total liabilities$34.78M$39.44M$29.22M$13.06M$13.38M-
Shareholders' equity-$1.01B-$994.95M-$1.10B-$1.10B$26.92M$9.86M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Operating cash flow-$120.12M-$126.35M-$90.07M-$77.09M-$50.30M-$25.18M
Capital expenditures$15.20M$29.51M$34.20M$1.85M$5.19M$5.46M
Free cash flow-$135.31M-$155.86M-$124.27M-$78.94M-$55.49M-$30.64M
Investing cash flow$103.97M$20.41M-$329.98M-$1.74M-$5.19M-$5.46M
Financing cash flow$25.57M$144.41M-$9.55M$548.52M$71.47M$19.99M
Share repurchases$0$0$9.50M$0$0-
Stock-based compensation$25.34M$29.37M$30.85M$74.47M$699.0K$730.0K
Depreciation and amortization$6.58M$5.43M$3.85M$3.04M$1.98M$964.0K

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Revenue growth, YoY1075.0%-----
Operating margin-18477.8%-241678.9%----
Net margin-7725.2%-80507.9%----
Free cash flow margin-15152.6%-205078.9%----
Return on equity-----204.9%-271.2%
Return on assets-20.6%-13.9%-8.4%-28.6%-136.8%-
Current ratio9.1310.9314.9446.422.21-

Source: XBRL data ProKidney Corp. files with the SEC, latest filing dated Nov 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

PROK peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
PROK$775.0K+4.2%-$103.28M-13326.7%$313.0M
VRTX$12.95B+10.5%$3.98B30.7%$136.35B
MESO$120.25M+599.2%-$57.50M-47.8%$1.62B
HUMA$2.40M+52.5%-$94.76M-3955.1%$149.6M
SANA---$149.27M-$563.3M
VERA---$415.31M-$1.95B
TVTX$651.03M+49.4%-$121.51M-18.7%$4.77B

PROK FAQ

7 questions
  • What is PROK revenue?
    ProKidney Corp. (PROK) reported $775.0K of revenue for the twelve months ended Sep 30, 2026. That is up 4.2% from the year before. Revenue for fiscal 2025 was $893.0K.
  • Is PROK profitable?
    No. ProKidney Corp. reported a net loss of $103.28M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does PROK have?
    ProKidney Corp. reported $81.36M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is PROK revenue growing?
    ProKidney Corp.'s revenue changed 12x in fiscal 2025, to $893.0K.
  • What is PROK free cash flow?
    ProKidney Corp. generated -$167.83M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$153.22M less capital expenditures.
  • When did PROK last report financial results?
    The latest statements here come from ProKidney Corp.'s 10-Q filed on Nov 12, 2026, covering the period ended Sep 30, 2026.
  • Where does this PROK financial data come from?
    Quantisnow builds these statements from the structured XBRL data ProKidney Corp. files with the SEC. It is provided for information only and is not investment advice.